Abstract
Systemic mastocytosis (SM) is a disease characterized by tissue infiltration of neoplastic mast cells originating from hematopoietic stem cells. Patients with advanced SM have a poor prognosis, and there is no mast cell ablative therapy available for most patients who carry an activating point mutation in the c-kit gene. We report results of a prospective study evaluating the safety, engraftment, and possibility of inducing a graft-versus-mast cell (GvMC) effect after allogeneic nonmyeloablative hematopoietic cell transplantation (HCT) from an HLA-identical sibling. Three patients with advanced SM were transplanted. All achieved complete donor T cell chimerism followed by clinical evidence for GvMC effect. However, all patients experienced disease progression with the longest response duration of 39 months. The GvMC effect can be observed after nonmyeloablative HCT with limited efficacy. Effective cytoreductive therapy prior to HCT may be required for long-term disease control and cure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akin C, Metcalfe DD . Systemic mastocytosis. Annu Rev Med 2004; 55: 419–432.
Metcalfe DD, Akin C . Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001; 25: 577–582.
Jaffe E, Harris LH, Stein H, Vardiman J . Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp. 49–55. Ref Type: Generic.
Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695–717.
Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C . Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998; 57: 24–28.
Ronnov-Jessen D, Lovgreen NP, Horn T . Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant 1991; 8: 413–415.
Fodinger M, Fritsch G, Winkler K, Emminger W, Mitterbauer G, Gadner H et al. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 1994; 84: 2954–2959.
Spyridonidis A, Thomas AK, Bertz H, Zeiser R, Schmitt-Graff A, Lindemann A et al. Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 515–519.
Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a Point Mutation in the Catalytic Domain of the Protooncogene c-kit in Peripheral Blood Mononuclear Cells of Patients who Have Mastocytosis with an Associated Hematologic Disorder. Proc Natl Acad Sci USA 1995; 92: 10560–10564.
Childs R, Clave E, Contentin D, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor chimerism precedes alloimmune responses. Blood 1999; 94: 3234–3241.
Sloand E, Childs RW, Solomon S, Greene A, Young NS, Barrett AJ . The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure hronic myelogenous leukemia. Bone Marrow Transplant 2003; 32: 897–901.
Nakamura R, Cortez K, Solomon S, Battiwalla M, Gill VJ, Hensel N et al. High-dose acyclovir and preemptive gancyclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 235–242.
Au WY, Chan AC, Lie AK, Chen FE, Liang R, Kwong YL . Recurrent isolated extramedullary relapses as granulocytic sarcomas following allogeneic bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant. 1998; 21: 205–208.
Lee KH, Lee JH, Kim S, Lee JS, Kim SH, Kim WK . High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26: 147–152.
Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van’t Wout JW, Verhoef G, Gerritis WB et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270–4276.
Tefferi A, Li CY, Butterfield JH, Hoagland HC . Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001; 344: 307–309.
Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A . Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004; 28: 127–131.
Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535–536.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214.
Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660–4666.
Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103: 473–478.
Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD . A novel form of systemic mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 3222–3225.
Corbin AS, Griswold IJ, La Rosee P, Yee KW, Heinrich MC, Reimer CL et al. Sensitivity of oncogeneic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 2004; 104: 3754–3757.
Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf III CA, Sundaranoorthi R et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood 2005; 106: 227–234.
Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Criffin JD et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106: 721–724.
Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865–2870.
Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T et al. A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005; 105: 2324–2331.
Fumo G, Akin C, Metcalfe DD, Neckers L . 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004; 103: 1078–1084.
Hasford J, Pfirrmann M, Hochhaus A . How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia 2005; 19: 497–499.
Stone RM . Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist 2004; 9: 259–270.
Peggs K, Mackinnon S . Imatinib mesylate – the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003; 348: 1048–1050.
Druker BJ . Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91: 1–30.
Acknowledgements
The authors would like to acknowledge our transplant coordinators and transplant nurses for their dedicated care of our patients, and all the members of the Bone Marrow Transplant Team for their constant support of the program. We also thank the Warren Grant Magnusson Clinical Center Intensive Care Unit for their exemplary patient care.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nakamura, R., Chakrabarti, S., Akin, C. et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 37, 353–358 (2006). https://doi.org/10.1038/sj.bmt.1705245
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705245
Keywords
This article is cited by
-
Pharmacological treatment options for mast cell activation disease
Naunyn-Schmiedeberg's Archives of Pharmacology (2016)
-
Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat
Indian Journal of Hematology and Blood Transfusion (2016)
-
Delayed graft-versus-mast-cell effect on systemic mastocytosis with associated clonal haematological non-mast cell lineage disease after allogeneic transplantation
Bone Marrow Transplantation (2013)
-
Die systemische Mastozytose – Standortbestimmung einer internistischen Erkrankung
Medizinische Klinik (2010)
-
Advanced mast cell disease: an Italian Hematological Multicenter experience
International Journal of Hematology (2008)